Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!
NASDAQ:ITEK
Delisted

Inotek Pharmaceuticals Corporation Fund Price (Quote)

$3.04
+0 (+0%)
At Close: Jan 22, 2018

Range Low Price High Price Comment
30 days $2.52 $3.25 Monday, 22nd Jan 2018 ITEK stock ended at $3.04. During the day the stock fluctuated 0% from a day low at $3.04 to a day high of $3.04.
90 days $1.96 $3.25
52 weeks $0.85 $3.80

Historical Inotek Pharmaceuticals Corporation prices

Date Open High Low Close Volume
Jan 28, 2016 $7.90 $8.02 $7.36 $7.60 229 900
Jan 27, 2016 $8.03 $8.18 $7.71 $7.82 98 600
Jan 26, 2016 $8.17 $8.20 $7.75 $8.13 154 800
Jan 25, 2016 $7.76 $8.30 $7.76 $8.15 127 400
Jan 22, 2016 $7.65 $7.84 $7.50 $7.82 169 600
Jan 21, 2016 $7.62 $7.82 $7.34 $7.43 188 300
Jan 20, 2016 $7.46 $7.81 $7.32 $7.66 209 200
Jan 19, 2016 $7.92 $7.98 $7.41 $7.62 246 200
Jan 15, 2016 $7.85 $7.91 $7.50 $7.79 185 500
Jan 14, 2016 $7.91 $8.44 $7.35 $8.08 262 000
Jan 13, 2016 $9.03 $9.16 $7.76 $7.89 186 900
Jan 12, 2016 $8.94 $9.33 $8.62 $9.01 109 500
Jan 11, 2016 $9.31 $9.51 $8.44 $8.89 348 600
Jan 08, 2016 $9.92 $10.15 $9.20 $9.25 391 000
Jan 07, 2016 $10.51 $10.66 $9.76 $9.81 320 800
Jan 06, 2016 $10.95 $11.00 $10.21 $10.66 343 000
Jan 05, 2016 $11.71 $11.89 $11.02 $11.12 353 600
Click to get the best stock tips daily for free!

About Inotek Pharmaceuticals Corporation

Inotek Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for glaucoma and other diseases of the eye in the United States. The company’s lead product candidate includes Trabodenoson, a monotherapy that is in Phase III clinical trials for lowering IOP by restoring the eye’s natural pressure control mechanism. It is also developing Trabodenoson plus La... ITEK Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT